The 90 references in paper E. Desport ., F. Bridoux ., C. Sirac ., S. Delbes ., S. Bender ., B. Fernandez ., N. Quellard ., C. Lacombe ., JM. Goujon ., D. Lavergne ., J. Abraham ., G. Touchard ., JP Fermand, A. Jaccard ., Э. Диспор ., Ф. Бриду ., К. Сирак ., С. Дельб ., С. Бендер ., Б. Фернандес ., Н. Келлар ., К. Лакомб ., Ж-М. Гужон ., Д. Лаверн ., ДЖ. Абрахам ., Г. Тушар ., Ж. Ферман -П., А. Жаккар . (2014) “AL-амилоидоз // AL-amyloidosis” / spz:neicon:nefr:y:2014:i:4:p:36-50

1
Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583–596
(check this in PDF content)
2
Kyle RA, Linos A, Beard CM et al. Incidence and natural history of primary systemic amyloidosis in Olmstead County, Minesota, 1950 through 1989. Blood 1992; 79: 1817–1822
(check this in PDF content)
3
Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 2005; 79: 319–328
(check this in PDF content)
4
Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010; 17(Suppl 1): 48–49
(check this in PDF content)
5
Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011; 29: 1924–1933
(check this in PDF content)
6
Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59
(check this in PDF content)
7
Obici L, Perfetti V, Palladini G et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005; 1753: 11–22
(check this in PDF content)
8
Pinney JH, Lachmann HJ, Bansi L et al. Outcome in renal AL amyloidosis after chemotherapy. J Clin Oncol 2011; 29: 674–681
(check this in PDF content)
9
Ekelund L. Radiological findings in renal amyloidosis. Am J Roentgenol 1977; 129: 851–853
(check this in PDF content)
10
Selvanayagam JB, Hawkins PN, Paul B et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007; 207(50): 2101–2110
(check this in PDF content)
11
Kappor P, Thenappan T, Singh E et al. Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med 2011; 124: 1006–1015
(check this in PDF content)
12
Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011; 97: 75–84
(check this in PDF content)
13
Loustaud-Ratti VR, Cypierre A, Rousseau A et al. Noninvasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid 2011; 18: 19–24
(check this in PDF content)
14
Terrier B, Jaccard A, Harousseau JL et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine 2008, 87: 99–109
(check this in PDF content)
15
Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine 1975; 54: 271–299
(check this in PDF content)
16
Sucker C, Hetzel GR, Grabensee B et al. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis 2006; 47: 947–955
(check this in PDF content)
17
Bouma B, Maas C, Hazenberg BP et al. Increased plasminalpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost 2005; 5: 1139–1142
(check this in PDF content)
18
Biewend ML, Menke DM, Calamia KT. The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature. Amyloid 2006; 13: 135–142
(check this in PDF content)
19
Paccalin M, Hachulla E, Cazalet C et al. Localized amyloidosis: a survey of 35 French cases. Amyloid 2005; 12: 239–245
(check this in PDF content)
20
Perfetti V, Vignarelli MC, Anesi E et al. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica 1999; 84: 218–221
(check this in PDF content)
21
Jaccard A, Moreau P, Leblond V et al. Myelome Autogreffe (MAG) and Intergroupe Francophone du Myelome (IFM) Intergroup: High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083–1093
(check this in PDF content)
22
Perfetti V, Coluccia AM, Intini D et al. Translocation T(4;14) (p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Am J Pathol 2001; 158: 1599–1603
(check this in PDF content)
23
Lachmann HJ, Gallimore R, Gillmore JD et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78–84
(check this in PDF content)
24
Serpell LC, Sunde M, Benson MD t al. The protofilament substructure of amyloid fibrils. J Mol Biol 2000; 300: 1033–1039
(check this in PDF content)
25
Sunde M, Serpell LC, Bartlam M et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 1997; 273: 729–739
(check this in PDF content)
26
Ozaki S, Abe M, Wolfenbarger D et al. Preferential expression of human λ-light chain variable region subgroups in multiple myeloma, AL amyloidosis, and Waldenstrцm’s macroglobulinemia. Clin Immunol Immunopathol 1994; 71: 183–189
(check this in PDF content)
27
Perfetti V, Palladini G, Casarini S et al. The repertoire of ŒЄ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 2012; 119: 144–150
(check this in PDF content)
28
Comenzo RL, Zhang Y, Martinez C et al. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001; 98: 714–720
(check this in PDF content)
29
Abraham RS, Geyer SM, Price-Troska TL et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 2003; 101: 3801–3808
(check this in PDF content)
30
Palladini G, Lavatelli F, Russo P et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107: 3854–3858
(check this in PDF content)
31
Brenner DA, Jain M, Pimentel DR et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004; 94: 1008–1010
(check this in PDF content)
32
Shi J, Guan J, Jiang B et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 2010; 107: 4188–4193
(check this in PDF content)
33
Libbey CA, Skinner M, Cohen AS. Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med 1983; 143: 1549–1552
(check this in PDF content)
34
Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinical useful test? Diagn Cytopathol 2004; 30: 178–181
(check this in PDF content)
35
Hachulla E, Grateau G. Diagnostic tools for amyloidosis. Joint Bone Spine 2002; 69: 538–545
(check this in PDF content)
36
Moumas E, Desport E, Lacombe C et al. Systemic AL amyloidosis with renal involvement in a region of Western France. Amyloid 2010; 17(Suppl 1): 151
(check this in PDF content)
37
Picken MM. New insights into systemic amyloidosis: the importance of diagnosis of specific type. Curr Opin Nephrol Hypertens 2007; 16: 196–203
(check this in PDF content)
38
Picken MM. Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med 2010; 134: 545–551
(check this in PDF content)
39
Touchard G. Ultrastructural pattern and classification of renal monoclonal immunoglobulin deposits. In Monoclonal gammopathies and the kidney. Edited by Touchard G, Aucouturier P, Hermine O, Ronco P. Dordrecht: Kluwer Academic Publishers; 2003: 95–117
(check this in PDF content)
40
Kyle RA, Therneau TM, Rajkumar SV et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362–1369
(check this in PDF content)
41
Veeramachaneni R, Gu X, Herrera GA. Atypical amyloidosis: diagnostic challenges and the role of immunoelectron microscopy in diagnosis. Ultrastruct Pathol 2004; 28: 75–82
(check this in PDF content)
42
Vrana JA, Gamez JD, Madden BJ et al. Classification of amyloidosis by laser microdissection and mass spectrometrybased proteomic analysis in clinical biopsy specimens. Blood 2009; 114: 4957–4959
(check this in PDF content)
43
Al-Zahrani GB, Bellavia D, Pellikka PA et al. Doppler myocardial imaging compared to standard two-dimensional and Doppler echocardiography for assessment of diastolic function in patients with systemic amyloidosis. J Am Soc Echocardiogr 2009; 22: 290–298
(check this in PDF content)
44
Syed IS, Glockner JF, Feng D et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3: 155–164
(check this in PDF content)
45
Dispenzieri A, Gertz MA, Kyle RA. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751–3757
(check this in PDF content)
46
Palladini G, Barassi A, Klersy C et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010; 116: 3426–3430
(check this in PDF content)
47
Kristen AV, Giannitsis E, Lehrke S et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010; 116: 2455–2461
(check this in PDF content)
48
Hawkins PN. Hereditary systemic amyloidosis with renal involvement. J Nephrol 2003; 16: 443–448
(check this in PDF content)
49
Lin J, Markowitz GS, Valeri AM et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12: 1482–1492
(check this in PDF content)
50
Nasr SH, Valeri AM, Cornell LD et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol 2012; 7: 231–239
(check this in PDF content)
51
Preud’homme JL, Cogne M, Bauwens M, et al. Structure of a monoclonal kappa chain of the VkappaIV subgroup in the kidney and plasma cells in light chain deposition disease. J Clin Invest 1991; 87: 2186–2190
(check this in PDF content)
52
Skinner M, Anderson J, Simms R et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100: 290–298
(check this in PDF content)
53
Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202–1207
(check this in PDF content)
54
Skinner M, Sanchorawala V, Seldin DC et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85–93
(check this in PDF content)
55
Sanchorawala V, Skinner M, Quillen K et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan an stem-cell transplantation. Blood 2007; 110: 3561–3563
(check this in PDF content)
56
Schonland SO, Bochtler T, Perz J et al. Results of two consecutive phase II trials of patients with systemic AL amyloidosis treated with high-dose melphalan after induction and mobilization chemotherapy [12th international symposium on amyloidosis abstracts]. Amyloid 2010; 17: 80–81
(check this in PDF content)
57
Cibeira MT, Sanchorawala V, Seldin DC et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011; 118: 4346–4352
(check this in PDF content)
58
Madan S, Kumar SK, Dispenzieri A et al. High-dose melphalan and peripheral blood stem cell transplantation for lightchain amyloidosis with cardiac involvement. Blood 2012; 119: 1117–1122
(check this in PDF content)
59
Vesole DH, Pйrez WS, Akasheh M et al. Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006; 81: 880–888
(check this in PDF content)
60
Goodman HJ, Gillmore JD, Lachmann HJ et al. Outcome of autologous stem cell transplantation for AL amyloidosis n the UK. Br J Haematol 2006; 134: 417–425
(check this in PDF content)
61
Palladini G, Perfetti V, Obici L et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936–2938
(check this in PDF content)
62
Wechalekar AD, Goodman HJ, Lachmann HJ et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457–464
(check this in PDF content)
63
Moreau P, Jaccard A, Benboubker L et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 doseescalation study. Blood 2010; 116: 4777–4782
(check this in PDF content)
64
Kastritis E, Wechalekar AD, Dimopoulos MA et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031–1037
(check this in PDF content)
65
Reece DE, Sanchorawala V, Hegenbart U et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114: 1489–1497
(check this in PDF content)
66
Mikhael JR, Schuster SR, Jimenez-Zepeda VH et al. Cyclophosphamide-bortezomib-dexamethasone (CYBORD) produces rapid and complete hematological response in patients with AL amyloidosis. Blood 2012; 119: 4398–4389
(check this in PDF content)
67
Venner CP, Lane T, Foard D et al. Cyclophosphamide, bortezomib and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression free survival. Blood 2012; 119: 4387–Inday
(check this in PDF content)
68
Comenzo RL, Vosburgh E, Simms RW et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996; 88: 2801–2806
(check this in PDF content)
69
Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662–3670
(check this in PDF content)
70
Landau H, Hassoun H, Bello C et al. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid 2011, 18(Suppl 1): 130–131
(check this in PDF content)
71
Dispenzieri A, Lacy MQ, Kyle RA et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001; 19: 3350–3356
(check this in PDF content)
72
Lebovic D, Hoffman J, Levine BM et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008; 143: 369–373
(check this in PDF content)
73
Gertz MA, Lacy MQ, Lust JA et al. Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica 2008; 93: 1402–1406
(check this in PDF content)
74
Gertz MA, Hayman SR, Buadi FK. Transplantation for IgM amyloidosis and IgM myeloma. Clin Lymphoma Myeloma 2009; 9: 77–79
(check this in PDF content)
75
Sanchorawala V, Wright DG, Rosenzweig M et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492–496
(check this in PDF content)
76
Dispenzieri A, Lacy MQ, Zeldenrust SR t al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109: 465–470
(check this in PDF content)
77
Kastritis E, Anagnostopoulos A, Roussou M et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007; 92: 1351–1358
(check this in PDF content)
78
Wechalekar AD, Lachmann HJ, Offer M et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295–298
(check this in PDF content)
79
Lamm W, Willenbacher W, Lang A et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol 2011; 90: 201–206
(check this in PDF content)
80
Zonder JA SV, Snyder RM, Matous J et al. Melphalan and dexamethasone plus bortezomib induces hematologic and organ responses in AL-amyloidosis with tolerable neurotoxicity. Blood (ASH Annual Meeting Abstracts) 2009; 114: 746
(check this in PDF content)
81
Tirzaman O, Wahner-Roedler DL, Malek RS et al. Primary localized amyloidosis ofthe urinary bladder: a case series of 31 patients. Mayo Clin Proc 2000; 75: 1264–1268
(check this in PDF content)
82
Sattianayagam PT, Gibbs SD, Pinney JH et al. Solid organ transplantation in AL amyloidosis. Am J Transplant 2010; 10: 2124–2131
(check this in PDF content)
83
Mignot A, Varnous S, Redonnet M et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis 2008; 101: 523–532
(check this in PDF content)
84
Herrmann SM, Gertz MA, Stegall MD et al. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant 2011; 26: 2032–2036
(check this in PDF content)
85
Bridoux F, Ronco P, Gillmore J, Fermand JP. Renal transplantation in light chain amyloidosis: coming out of the cupboard. Nephrol Dial Transplant 2011; 26: 1766–1768
(check this in PDF content)
86
Guidelines Working Group of UK Myeloma Forum: British Commitee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125: 681–700
(check this in PDF content)
87
Pardanani A, Witzig TE, Schroeder G et al. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003; 101: 827–830
(check this in PDF content)
88
Hasserjian RP, Goodman HJB, Lachmann HJ et al. Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis. Histopathology 2007; 50: 567–573
(check this in PDF content)
89
Pepys MB, Herbert J, Hutchinson WL et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417: 254–259
(check this in PDF content)
90
Bodin K, Ellmerich S, Kahan MC et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010; 468: 93–97 Заявление о конфликте интересов Frank Bridoux заявил, что Arnaud Jaccard получил гонорар
(check this in PDF content)